{"recordId":"st_2xf64x5nckndfl4l","canonicalUrl":"https://sotwire.com/stories/precision-biosciences-125-million-offering-gene-editing-durham","jsonUrl":"https://sotwire.com/stories/precision-biosciences-125-million-offering-gene-editing-durham/record","slug":"precision-biosciences-125-million-offering-gene-editing-durham","headline":"Precision BioSciences raises $125 million","dek":"The Durham gene editing company priced a stock offering to keep funding its hepatitis B and Duchenne muscular dystrophy programs.","articleBody":"Precision BioSciences, the Durham clinical stage gene editing company, announced on Nov. 5 that it priced an underwritten offering expected to bring in about $125 million in gross proceeds, before underwriting discounts, commissions and offering expenses. The offering was expected to close on or about Nov. 6.\n\nThe company sold 10,235,077 shares of common stock at $7.75 a share and, to certain investors in place of common stock, pre-funded warrants to buy up to 5,893,964 shares. New and existing investors took part, including First Light Asset Management, MPM BioImpact, Bleichroeder LP, Lynx1 Capital Management, Readout Capital, Aberdeen Investments and Driehaus Capital Management. TD Cowen and Guggenheim Securities served as joint book-running managers.\n\nPrecision said it plans to use the net proceeds to keep developing PBGENE-HBV, its program for chronic hepatitis B, and PBGENE-DMD, its program for Duchenne muscular dystrophy, as well as for working capital and general corporate purposes.\n\nThe raise came the same day the company shared Phase 1 ELIMINATE-B data for PBGENE-HBV ahead of the AASLD Liver Meeting. Precision said it has selected a 0.4 mg/kg go-forward dose and is starting a global Phase 2 study called ELIMINATE-B2. The company builds its in vivo gene editing candidates on ARCUS, its own genome editing platform, and trades on Nasdaq as DTIL.","category":"funding","categoryLabel":"Funding","location":"Durham, NC","company":{"name":"Precision BioSciences","domain":"precisionbiosciences.com"},"sample":false,"sampleDisclaimer":null,"publishedAt":"2026-11-11T14:19:38.297Z","updatedAt":"2026-11-11T14:19:38.297Z","badge":"Desk reported","trust":{"level":"desk_reported","doctrine":"Sotwire verifies who at the company stood behind the submission. It does not independently certify every underlying company claim as true.","verifies":"which named Sotwire editor wrote this from the cited sources","doesNotCertify":"independent truth of every claim","badge":"Desk reported","verificationMethod":"Named Sotwire editor, from the cited sources. Not a company attestation, and not an independent fact-check of every sentence.","domainChecked":false},"attestation":{"attested":false},"confirmation":null,"facts":[{"label":"Gross proceeds","value":"About $125 million"},{"label":"Price","value":"$7.75 per share"},{"label":"Book-running managers","value":"TD Cowen and Guggenheim Securities"},{"label":"Programs funded","value":"PBGENE-HBV and PBGENE-DMD"}],"keyEvents":[{"date":"2026-11-05","label":"Offering priced"},{"date":"2026-11-06","label":"Expected closing"}],"sources":[{"url":"https://www.businesswire.com/news/home/20261104579338/en/Precision-BioSciences-Announces-Pricing-of-%24125-Million-Underwritten-Offering-of-Common-Stock-and-Pre-Funded-Warrants","title":"Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants","publisher":"Business Wire / Precision BioSciences"},{"url":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026071304/ex991pricingpressreleasefi.htm","title":"Exhibit 99.1: Pricing press release","publisher":"U.S. Securities and Exchange Commission (Precision BioSciences filing)"},{"url":"https://www.businesswire.com/news/home/20261105643191/en/Precision-BioSciences-Announces-Late-Breaking-PBGENE-HBV-Data-at-AASLD-The-Liver-Meeting-2026-Further-Demonstrating-cccDNA-Elimination-and-Potential-to-Drive-Viral-Cure","title":"Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting 2026","publisher":"Business Wire / Precision BioSciences"}],"source":{"url":"https://www.businesswire.com/news/home/20261104579338/en/Precision-BioSciences-Announces-Pricing-of-%24125-Million-Underwritten-Offering-of-Common-Stock-and-Pre-Funded-Warrants","publisher":"Precision BioSciences","publishedAt":"2026-11-05T05:00:00.000Z"},"cover":{"url":"https://sotwire.com/covers/precision-biosciences-125-million-offering-gene-editing-durham.webp","alt":"Precision BioSciences raises $125 million","provenance":"unknown","provenanceLabel":"Unknown origin","credit":null},"images":[],"provenanceMethod":"EXIF, XMP, and filename heuristic. Not C2PA cryptographic proof, and not a judgment that the depicted event is true.","provenanceDisclaimer":"v1 labels are heuristic (EXIF, XMP, filename), not cryptographic C2PA proof. Treat them as disclosure of observed metadata, not a guarantee that the image is genuine or that the depicted event is true.","citation":"Sotwire Desk, Precision BioSciences. \"Precision BioSciences raises $125 million.\" Sotwire, November 11, 2026, https://sotwire.com/stories/precision-biosciences-125-million-offering-gene-editing-durham. Record ID: st_2xf64x5nckndfl4l. Desk reported.","sampleLabel":null,"correctionStatus":"No public corrections recorded","integrity":{"algorithm":"sha-256","hex":"1966589fd8ad35ce2d30f49fd4b41d680ec645a3d235e0ad11ada726f408621a","contentDigest":"sha-256=:GWZYn9itNc4tMPSf1LQdaA7GRaPSNeCtEa2nJvQIYho=:","scope":"Canonical JSON record excluding the integrity object"}}